Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Inpatients and outpatients meeting the diagnostic criteria probable VaD established according to the Diagnostic and Statistical Manual of Mental Disorders (fourth edition) （DSM-Ⅳ） and the National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN)were eligible to participate,~* diagnosis of mild to moderate vascular dementia;~* Chinese-speaking patients aged ≥45 and≤85 years old in both gender;~* weighing between 45 and 90kg;~* fully conscious;~* MMSE score of≤26 and ≥14;~* HIS score of ≥7;~* adequate vision and hearing ability to complete all study tests;~* with a stable caregiver.~Exclusion Criteria:~Patients will be excluded from the enrollment if they meet any of the followings:~* a medical history of other dementia types, like Alzheimer's disease, Parkinson's disease dementia, Huntington disease, Normal pressure hydrocephalus, et al;~* major depression (HAMD for 17 items\>17) or psychotic disorder;~* acute stage of cerebral hemorrhage or subarachnoid hemorrhage;~* hypothyroidism;~* drug or alcohol abuse;~* epilepsy history; myasthenia gravis history;~* severe cardiovascular disease(severe arrhythmia with heart rate≥100 or≤60 times per min, left bundle branch block, myocardial infarction within 3 months, systolic pressure≥180mmHg or ≤90mmHg);~* severe liver or kidney dysfunction (alanine aminotransferase\>60 IU/L, aspartate transaminase\>60 IU/L or serum creatinine \>266μmol/L);~* severe asthma or chronic obstructive pulmonary disease;~* gastrointestinal tract obstruction or severe peptic ulcer; glaucoma;~* administration of cholinesterase inhibitors, memantine or nimodipine in the last month;~* use of sympathomimetic agent, antihistamine drug, antianxiety drugs or tranquilizer within 48h before assessment;~* use of antipsychotic drugs within 72h before assessment;~* participation in other clinical trials; allergic history to any type of medication used in this study.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Tianzhi granule (Type: EXPERIMENTAL): Tianzhi granule and placebo identified to donepezil
- Donepezil (Type: ACTIVE_COMPARATOR): Donepezil and placebo identified to Tianzhi granule
- Placebo (Type: PLACEBO_COMPARATOR): Placebo identified toTianzhi granule and placebo identified to donepezil

Based on this trial design, predict the completion outcome and termination type (if applicable).